Antimicrobial susceptibility of gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015

Journal of Medical Microbiology

Volumn 66, Issue 1, 2017, Pages 61-69

  Karlowsky, James A ^a   Hoban, Daryl J ^a,b   Hacke, Meredith A ^b   Lob, Sibylle H ^b   Sahm, Daniel F ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b International Health Management Associates   (United States)

Author keywords

Asia Pacific; Ertapenem; ESKAPE pathogens; Imipenem; SMART; Surveillance

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; BETA LACTAM; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; ASIA PACIFIC; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; ENTEROBACTER; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HOSPITALIZATION; INTRAABDOMINAL INFECTIONS; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; URINARY TRACT INFECTIONS;

ACINETOBACTER BAUMANNII; AMIKACIN; ANTI-INFECTIVE AGENTS; ASIA; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; GRAM-NEGATIVE BACTERIA; HOSPITALIZATION; HUMANS; IMIPENEM; INTRAABDOMINAL INFECTIONS; KLEBSIELLA PNEUMONIAE; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTIONS;

EID: 85014390378     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000421     Document Type: Article

References (21)

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079-1081.
2. Pogue JM, Kaye KS, Cohen DA, Marchaim D. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect 2015;21:302-312.
3. Bodro M, Sabe N, Tubau F, Lladó L, Baliellas C et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013;96:843-849.
4. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010;31:S7-S10.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
6. Biedenbach D, Bouchillon S, Hackel M, Hoban D, Kazmierczak K et al. Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012. Antimicrob Agents Chemother 2015;59:826-830.
7. Paterson DL, Rossi F, Baquero F, Hsueh P-R, Woods GL et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-973.
8. Sheng WH, Badal RE, Hsueh PR. Distribution of extended-spectrum b-lactamases, AmpC b-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013;57:2981-2988.
9. Lu P-L, Liu Y-C, Toh H-S, Lee Y-L, Liu Y-M et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012;40:S37-S43.
10. Liu Y-M, Chen Y-S, Toh H-S, Huang C-C, Lee Y-L et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012;40:S11-S17.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Twenty-Fifth Informational Supplement M100-S25. Wayne, PA, USA: CLSI; 2015.
12. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 10th ed, Approved Standard M07-A10. Wayne, PA, USA: CLSI; 2015.
13. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-164.
14. Jean S-S, Coombs G, Ling T, Balaji V, Rodrigues C et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. Int J Antimicrob Agents 2016;47:328-334.
15. Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010. Int J Antimicrob Agents 2012;39:490-495.
16. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-210.
17. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010;36:S8-S14.
18. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 2016;47:317-323.
19. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011;1:47.
20. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014;78:443-448.
21. Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF. Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013. J Glob Antimicrob Resist 2015;3:190-197.